Neuraxpharm Strikes Long-Acting Injectables Deal With Pharmathen
The Agreement Grants Neuraxpharm Exclusive European Rights To The Therapies
The two companies have signed a co-development agreement focused on the potential creation of new long-acting injectable therapies for psychiatric conditions for an undisclosed financial sum.
